NCT05347641View on ClinicalTrials.gov

Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System Lymphoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

June 1, 2025

Study Completion Date

June 1, 2029

Conditions
Primary Central Nervous System Lymphoma
Interventions
DRUG

Penpulimab

"Penpulimab + RMA regimen:~Rituximab 375 mg/m2 d0 iv Methotrexate (MTX) 3.5g/m2 drip D1 Cytarabine \* (ARA-C) 1-2g/m2 q12H D2-3 iv Penpulimab 200 mg iv D5"

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER

NCT05347641 - Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System Lymphoma | Biotech Hunter | Biotech Hunter